Massana E, Barbanoj M J, Moros C, Morte A, Gich I, Jané F
Hospital de la Santa Creu i Sant Pau, Departament de Farmacologia i Terapèutica, UAB, Barcelona, Spain.
Pharmacol Res. 1997 Jul;36(1):41-7. doi: 10.1006/phrs.1997.0202.
Captopril is an angiotensin-converting enzyme inhibitor (ACEI) used in the treatment of hypertension and congestive heart failure and has demonstrated its cardiovascular effects in experimental animal models, healthy volunteers and patients. The aim of this study was to find out whether or not differences in the pharmacokinetic profile and the haemodynamic response of a 100-mg single oral dose of captopril appeared between subjects of both sexes. Twenty-four young healthy volunteers (12 males and 12 females) took part in the trial. Blood samples to assess captopril plasma concentrations, determined by reverse phase high performance liquid chromatography (HPLC), as well as haemodynamic variables, were obtained before and at different times following drug intake. Pharmacokinetic parameters did not show significant sex differences. Systolic and diastolic blood pressure exhibited a statistically significant decrease between 0.5 and 8 h in both sexes. No significant sex-related differences were found. The drug exhibited a good tolerability.
卡托普利是一种血管紧张素转换酶抑制剂（ACEI），用于治疗高血压和充血性心力衰竭，并已在实验动物模型、健康志愿者和患者中证明了其心血管作用。本研究的目的是找出单剂量口服100毫克卡托普利后，男女受试者在药代动力学特征和血流动力学反应方面是否存在差异。24名年轻健康志愿者（12名男性和12名女性）参与了试验。在服药前及服药后的不同时间采集血样，通过反相高效液相色谱法（HPLC）测定卡托普利血浆浓度，并获取血流动力学变量。药代动力学参数未显示出显著的性别差异。男女两性的收缩压和舒张压在0.5至8小时之间均出现了统计学上的显著下降。未发现明显的性别相关差异。该药物具有良好的耐受性。
